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The evolutionarily conserved 18-glycosyl-
hydrolase family contains true chitinases and mol-
ecules that lack chitinase activity (1–4). Much of 
the research in this area has focused on chitin-
ases, like acidic mammalian chitinase (AMCase), 
that play critical roles in the life cycle of parasites 
(5, 6) and the pathogenesis of Th2 and antipara-
site responses (3, 4, 7). However, the majority of 
the 18-glycosyl-hydrolase family members are 
chitinase-like proteins (CLPs), which, as a result 
of mutations in their highly conserved enzyme 
sites, do not contain chitinase activity. Breast re-
gression protein 39 (BRP-39) and its human ho-
mologue YKL-40 (also called chitinase 3-like-1 
and human cartilage glycoprotein [HcGP] 39) 
(8–10) are the prototypes of these enzymatically 
deficient CLPs. Surprisingly, their roles in biol-
ogy have only been superficially addressed.
BRP-39 and YKL-40 are produced by a va-
riety of cells including neutrophils, monocytes, 
macrophages, chondrocytes, synovial cells, smooth 
muscle cells, endothelial cells, and tumor cells 
(3, 8, 11). Increased levels of YKL-40 protein 
and/or messenger RNA (mRNA) have been 
noted in patients with a broad spectrum of pa-
thologies including bacterial infections, rheuma-
toid arthritis, osteoarthritis, giant cell arteritis, 
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Mouse breast regression protein 39 (BRP-39; Chi3l1) and its human homologue YKL-40 are 
chitinase-like proteins that lack chitinase activity. Although YKL-40 is expressed in exag-
gerated quantities and correlates with disease activity in asthma and many other disorders, 
the biological properties of BRP-39/YKL-40 have only been rudimentarily defined. We 
describe the generation and characterization of BRP-39/ mice, YKL-40 transgenic mice, 
and mice that lack BRP-39 and produce YKL-40 only in their pulmonary epithelium. Stud-
ies of these mice demonstrated that BRP-39/ animals have markedly diminished antigen-
induced Th2 responses and that epithelial YKL-40 rescues the Th2 responses in these 
animals. The ability of interleukin13 to induce tissue inflammation and fibrosis was also 
markedly diminished in the absence of BRP-39. Mechanistic investigations demonstrated 
that BRP-39 and YKL-40 play an essential role in antigen sensitization and immunoglobulin 
E induction, stimulate dendritic cell accumulation and activation, and induce alternative 
macrophage activation. These proteins also inhibit inflammatory cell apoptosis/cell death 
while inhibiting Fas expression, activating protein kinase B/AKT, and inducing Faim 3. These 
studies establish novel regulatory roles for BRP-39/YKL-40 in the initiation and effector 
phases of Th2 inflammation and remodeling and suggest that these proteins are therapeu-
tic targets in Th2- and macrophage-mediated disorders.
© 2009 Lee et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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used in the evaluation (unpublished data). Interestingly, similar 
induction of BRP-39 was seen in lungs from mice sensitized 
and challenged with the chitin-containing antigen house dust 
mite (HDM) extract (Fig. 1 F and not depicted). Thus, BRP-39 
is prominently induced during the course of chitin-free and 
chitin-containing antigen-induced Th2 inflammation.
Generation and preliminary characterization  
of BRP-39/ mice
Homologous recombination was subsequently used to gener-
ate BRP-39/ mice. The constructs that were used elimi-
nated exons 1–6 and part of the BRP-39 promoter (Fig. S1). 
PCR, mRNA, and Western evaluations demonstrated the 
success of this approach (Fig. S1, B–D). These mice were bred 
for >10 generations onto a C57BL/6 or BALB/c background. 
At baseline, the BRP-39/ mice were viable and fertile and 
were not able to be differentiated from the WT littermate 
controls based on size, physical appearance, rate of growth, or 
level of physical activity (unpublished data). In addition, au-
topsy, light microscopic examinations of skin and visceral 
organs, pulmonary compliance assessments, and H&E, tri-
chrome, and elastin evaluations failed to reveal differences 
between WT and BRP-39/ animals (unpublished data).
Role of BRP-39 in OVA-induced Th2 inflammation  
and physiological dysregulation
In WT mice, OVA-plus-alum sensitization and challenge caused 
a significant increase in tissue inflammation and bronchoalveolar 
lavage (BAL) total cell, eosinophil, and lymphocyte recovery 
(Fig. 2 A and Fig. S2). In these mice, increased numbers of CD4 
Th2 cells and alternatively activated macrophages (M2 macro-
phages) were also seen (Fig. 2, B and C; Fig. S3; and not de-
picted). Exaggerated bronchospastic responses to methacholine 
challenge (airways hyperresponsiveness [AHR]; Fig. 2 D) and 
increased BAL Muc5ac and mucus metalasia were also noted 
(Fig. 2 E and not depicted). Similar responses were elicited in 
mice that were sensitized and challenged with the HDM extract 
(Fig. 2 F and data not depicted). In both experimental systems, 
each of these inductive events was at least partially BRP-39 de-
pendent because null mutations of BRP-39 caused a significant 
decrease in each of these parameters (Fig. 2, A–F and Fig. S2). 
Importantly, these effects appeared to be at least partially Th2 
specific because OVA-plus-complete-Freund’s-adjuvant–in-
duced Th1 inflammation and IFN- production were not simi-
larly altered in BRP-39/ mice (Fig. 2, G and H).
In WT mice, OVA-plus-alum sensitization and challenge 
caused significant increases in Th2 cytokine mRNA and pro-
tein (Fig. 2 I and not depicted). Comparable Th2 cytokine in-
duction was not noted in mice with null mutations of BRP-39, 
with lung IL-13 and IL-4 being decreased by ≥80% (Fig. 2 I 
and not depicted). When viewed in combination, these studies 
demonstrate that BRP-39 plays a critical role in Th2 inflam-
mation, physiological dysregulation, mucus metaplasia, and 
Th2 cytokine elaboration. They also demonstrate that BRP-39 
plays a similar role in chitin-free and chitin-containing anti-
gen-induced responses.
sarcoidosis, scleroderma, diabetes, atherosclerosis, inflamma-
tory bowel disease, and solid malignancies (3, 8, 11–16). In 
many of these disorders, the levels of YKL-40 reflect the ac-
tivity and natural history of the disease (2, 14–16). This is 
nicely illustrated in studies from our laboratory and from others, 
which have demonstrated that elevated levels of serum YKL-40 
are seen in patients with asthma which correlate with the 
levels of lung tissue YKL-40 and disease severity (2). These 
studies also highlighted polymorphisms in chitinase 3-like-1 
that correlated with the levels of circulating YKL-40, the 
presence of asthma, and compromised lung function (17). 
The potential importance of YKL-40 can also be seen in 
rheumatoid arthritis, coronary artery disease, solid cancers, 
and death in the elderly, where elevated serum YKL-40 levels 
correlate with the severity of joint involvement, the number 
of blocked coronary arteries, short disease-free intervals, and 
all-cause mortality, respectively (11, 14, 15, 18). As a result, 
YKL-40 is a prognostic biomarker and has been proposed to 
be a therapeutic target in conditions characterized by acute or 
chronic inflammation, extracellular matrix remodeling, fibro-
sis, and cancer (11, 18, 19). Because serum YKL-40 levels 
provide information that is different than that provided by 
established prognostic biomarkers, such as serum C-reactive 
protein, YKL-40 is believed to reflect different pathways in 
the pathogenesis of these disorders (11). However, our very 
limited understanding of the biology of BRP-39/YKL-40 
makes it difficult to appreciate the true meaning of these dis-
ease-CLP associations and the ways that BRP-39 and YKL-40 
contribute to normal biology and disease-relevant pathologi-
cal responses. This is due, in part, to the fact that mice with 
null mutations of CLP and mice that overexpress CLP have 
not been generated, thereby limiting mouse modeling of 
these molecules. To address this deficiency and further define 
the biology of CLP, we generated and characterized mice with 
null mutations of BRP-39 (BRP-39/), mice that overexpress 
YKL-40 in a lung-specific fashion, and mice that lack BRP-39 
and produce YKL-40 only in their respiratory epithelium.
RESULTS
Regulation of BRP-39 by Th2 inflammation
To determine if BRP-39 is regulated by Th2 inflammation, 
we compared the expression of BRP-39 in lungs from control 
mice and mice that had been sensitized and challenged with 
the chitin-free antigen OVA. These studies demonstrated that 
the levels of BRP-39 mRNA and protein were significantly 
increased after OVA sensitization and challenge (Fig. 1, A–C). 
This was readily detected 24 h after aerosol OVA exposure and 
persisted at all time points that were assessed (Fig. 1 and not 
depicted). This induction was not seen in mice that received a 
saline aerosol after OVA-plus–aluminum hydroxide (alum) 
sensitization or an OVA aerosol after saline sensitization (un-
published data). In all cases, BRP-39 was induced predomi-
nantly in airway epithelial cells and alveolar macrophages (Fig. 1, 
D and E). This staining was appropriately specific because it 
was not present when the primary antibody was preincubated 
with BRP-39 peptide and when the primary antibody was not 
JEM VOL. 206, May 11, 2009 
ARTICLE
1151
BRP-39 significantly decreased each of these parameters (Fig. 3, 
A and B). In combination, these studies demonstrate that 
BRP-39 plays a critical role in antigen-induced sensitization 
and IgE induction.
BRP-39 regulation of pulmonary DCs
To further define the defects in antigen sensitization that were 
noted, we next compared the myeloid DC (mDC) and plas-
macytoid DC (pDC) in lungs from WT and BRP-39/ mice. 
In these experiments, the numbers of mDC and pDC were 
increased in lungs from WT mice that had been sensitized 
and challenged with OVA (Fig. 3, C and D). The mDC also 
Role of BRP-39 in antigen sensitization and IgE induction
To begin to assess the mechanisms that underlie the defective 
Th2 responses in BRP-39/ mice, studies were undertaken 
to determine if BRP-39 played a role in OVA-induced aller-
gen sensitization. In these experiments, WT and BRP-39/ 
mice received i.p. OVA plus alum. They were then boosted 
with antigen and antigen-induced splenocyte proliferation 
and the levels of antigen-specific IgE were assessed. In WT mice, 
sensitization resulted in readily appreciable antigen-induced 
splenocyte proliferation and increases in the levels of antigen-
specific IgE (Fig. 3, A and B). Each of these responses was at 
least partially BRP-39 dependent because null mutations of 
Figure 1. Regulation of BRP-39 during antigen-induced Th2 inflammation. (A–F) WT BALB/c mice were sensitized with OVA plus alum and chal-
lenged with PBS or OVA (A–E) or sensitized with HDM antigen plus alum and challenged with PBS or HDM (F). (A) The levels of BRP-39 mRNA were evalu-
ated by real time RT-PCR. (B and C) BRP-39 accumulation was assessed via Western analysis (B) and ELISA (C) using lung lysate and BAL fluid, respectively. 
(D) Immunohistochemistry (IHC) was also used to localize the BRP-39 (solid arrow, airway epithelial cell; open arrow, alveolar macrophage). (E) Double-label 
IHC using BRP-39 and F4/80 antibodies, localized BRP-39, and F4/80-positive macrophages (white arrows, double+ cells). (F) The levels of BRP-39 in BAL 
fluids from PBS- or HDM-challenged mice, assessed by ELISA. Values in A, C, and F are the mean ± SEM of evaluations in a minimum of five animals and are 
representative of two separate evaluations. B, D, and E are illustrative of a minimum of three separate experiments. **, P < 0.01. Bars, 25 µm.
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Figure 2. Antigen-induced responses in BRP-39/ mice. (A–C) BALB/c WT (+/+) and BRP-39/ mice were sensitized and challenged with OVA 
(OVA+) or PBS (OVA). 24 h later, BAL total (Tot) cell, macrophage (Mac), eosinophil (Eos), lymphocyte (Lym), and neutrophil (Neu) recovery were quanti-
tated (A), IL-4– and IL-13–expressing Th2 cells were assessed (B), and MMR expressing alternatively activated macrophages were quantitated (C). (D) AHR 
was addressed by comparing the airways resistance and elastance of OVA-sensitized and -challenged WT mice (solid circles and solid lines) and BRP-
39/ mice (solid squares and solid lines), WT mice sensitized with OVA and challenged with PBS (circles and dashed lines), and BRP-39/ mice sensi-
tized with OVA and challenged with PBS (squares and dashed lines). (E) Levels of Muc5ac in the BAL were quantitated by densitometry after slot blotting 
and immunodetection. (F) WT (+/+) and BRP-39/ mice were also sensitized and challenged by HDM extract, and BAL cells were evaluated 1 d after the 
last challenge. (G and H) In evaluations of Th1 responses, WT (+/+) and BRP-39/ mice were sensitized with CFA/OVA (CFA/OVA+) or PBS (CFA/OVA) and 
challenged by OVA. 24 h after the last challenge, BAL cell recovery (G) and BAL IFN- levels (H) were evaluated. (I) ELISA evaluations were also used to 
quantitate the levels of BAL IL-13 and IL-4 in OVA-induced Th2 responses. The values are the mean ± SEM of evaluations in a minimum of five animals 
and are representative of at least three independent experiments. MFI, median fluorescence intensity; ns, not significant. *, P < 0.05; **, P < 0.01.
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not however, rule out the possibility that BRP-39 also plays 
a critical role in Th2 effector responses. Because IL-13 is 
the major effector at sites of Th2 inflammation, we addressed 
this possibility by determining if IL-13 regulates BRP-39 
and defining the roles of BRP-39 in the pathogenesis of 
IL-13–induced inflammation and tissue remodeling. The for-
mer studies demonstrated that the levels of BRP-39 mRNA 
and protein were significantly higher in lungs from IL-13 
transgenic (Tg) mice compared with the WT controls (Fig. 4, 
A and B). This BRP-39 was most prominent in airway epithelial 
cells and alveolar macrophages (Fig. 4 C). Double-label IHC 
demonstrated that many of the BRP-39–positive cells were 
CC10+ airway epithelial cells, Pro–surfactant protein C+ alveolar 
type 2 epithelial cells, and CD45+ macrophages (Fig. 4 D). 
expressed increased levels of CD86, CD80, and CD40 com-
pared with cells from control mice (Fig. 3 E). BRP-39 
played an important role in these responses because mDC 
and pDC accumulation and mDC expression of CD86 and 
CD40 were significantly decreased in lungs from sensitized 
and challenged BRP-39/ mice (Fig. 3, C–E). In contrast, 
comparable levels of mDC CD80 were seen in the presence 
and absence of BRP-39 (Fig. 3 E). These studies demon-
strate that BRP-39 plays a critical role in the accumulation 
and activation of pulmonary DC.
BRP-39 in IL-13–induced tissue responses
The studies noted in the previous sections demonstrate that 
BRP-39 plays a critical role in allergen sensitization. They do 
Figure 3. BRP-39 regulation of antigen sensitization. Splenocytes were isolated from the BALB/c WT and BRP-39/ mice that were sensitized and 
challenged by PBS (OVA) or OVA (OVA+). (A and B) After restimulation with OVA, splenocyte proliferation was assessed by BrdU staining (A), and OVA-specific 
IgE levels (B) were evaluated by ELISA. (C–E) FACS was used to assess mDC (C) and pDC (D) numbers and mDC expression of CD86, CD40, and CD80 (E) in 
lungs from WT and BRP-39/ mice that were or were not sensitized and challenged with OVA. The values are the mean ± SEM of evaluations in a minimum 
of five animals and are representative of three separate experiments. MFI, median fluorescence intensity; ns, not significant. *, P < 0.05; **, P < 0.01.
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Figure 4. Regulation and roles of BRP-39 in IL-13–induced tissue responses. (A and B) Real-time RT-PCR and Western analysis were used to 
evaluate the levels of mRNA encoding BRP-39 (A) and BALF BRP-39 protein (B) in lungs from C57BL/6 WT (+/+) and IL-13 Tg mice. (C) The localization of 
the BRP-39 was evaluated with IHC. Solid arrow, airway epithelium; open arrow, macrophage. (D) Further cellular localization was obtained via double-
label IHC using BRP-39 and cell-specific antibodies (CC10, airway epithelial cells; pro-SPC, alveolar type II cells; CD45, leukocytes). Arrows, positive for 
both antibodies. (E and F) Using WT and IL-13 Tg mice with WT (+/+) and null (/) BRP-39 loci, FACS was used to assess BAL CD4+ Th2 cells (E) and 
histological evaluations were used to evaluate inflammation and airway remodeling (F; left and center are H&E stains [open arrows, peribronchial fibrosis; 
solid arrow, inflammation] and right are Mallory’s trichrome stains [open arrows, subepithelial fibrosis). (G and H) Total collagen content of the right lung 
and the levels of BAL total TGF-1 were quantitated by Sircol collagen assay (G) and ELISA (H), respectively. The values in A, E, G, and H are the mean ± 
SEM of evaluations in a minimum of four animals and are representative of three separate evaluations. B, C, D, and F are illustrative of a minimum of 
three separate experiments. MFI, median fluorescence intensity. *, P < 0.05; **, P < 0.01. Bars, 25 µm.
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In the latter experiments, IL-13 Tg mice with WT and null 
BRP-39 loci were generated and the tissue effects of IL-13 in 
these animals were compared. As previously reported (20, 21), 
IL-13 caused an eosinophil-, macrophage-, and CD4 Th2 
cell–rich inflammatory response and peribronchial fibrosis 
(Fig. 4, E–G; and not depicted). The BAL and tissue inflam-
mation, CD4 T cell accumulation, and histological and bio-
chemical assessments of tissue fibrosis were significantly 
decreased in BRP-39/ mice (Fig. 4 E–G; and not depicted). 
In accord with our prior demonstration that IL-13 induces 
airway fibrosis, in part by inducing and activating TGF-1 
(22), the levels of BAL TGF-1 were also significantly de-
creased in Tg mice that lacked BRP-39 (Fig. 4 H). Impor-
tantly, comparable levels of IL-13 were produced in Tg mice 
Figure 5. Roles of BRP-39 in inflammatory cell apoptosis/cell death in vivo. BALB/c WT (+/+) and BRP-39/ mice were sensitized and challenged 
with OVA (OVA+) or PBS (OVA). (A–C) Apoptosis was evaluated using TUNEL stains (A) and FACS evaluations to evaluate the expression of annexin V  
(B), and annexin V and the uptake of PI (C). (D) The expression of Fas was also evaluated by flow cytometry. (E and F) In the C57BL/6 WT and IL-13 Tg mice 
with WT and null BRP-39 loci, annexin V+ CD4 T cells and macrophages (E) and active caspase 3 expression (F) were evaluated by FACS and Western blot 
analysis, respectively. The values in A, B, D, and E are the mean ± SEM of evaluations in a minimum of five animals and are representative of at least three 
separate evaluations. C and F are representative of five and two experiments, respectively. MFI, median fluorescence intensity. *, P < 0.05; **, P < 0.01.
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in IL-13 Tg mice that were deficient in BRP-39 were also asso-
ciated with enhanced TUNEL staining, enhanced levels of 
CD4 cell and macrophage apoptosis, and enhanced levels of 
caspase 3 activation (Fig. 5, E and F; and not depicted). These 
studies demonstrate that BRP-39 is an important inhibitor of 
eosinophil, T cell, and macrophage death receptor–mediated 
apoptosis/cell death in vivo.
BRP-39 regulation of apoptosis-inhibiting pathways in vivo
To shed light on the pathways that BRP-39 uses to control 
inflammatory cell apoptosis, we evaluated known apoptosis-
inhibiting pathways in OVA-plus-alum–sensitized and –chal-
lenged WT and BRP-39/ mice. These studies demonstrated 
that the decreased levels of apoptosis in WT compared with 
BRP-39/ mice were associated with enhanced levels of 
total and activated protein kinase B (PKB)/AKT (Fig. 6 A 
and not depicted). Similarly, they were associated with en-
hanced levels of expression of Fas apoptosis-inhibiting mole-
cule (Faim) 3 (Fig. 6 B).
BRP-39 regulation of inflammatory cell apoptosis in vitro
Studies were next undertaken to determine if BRP-39 directly 
regulated inflammatory cell apoptosis in vitro and to evaluate 
the lung specificity of the effects that were seen. In these ex-
periments, we compared the cell death responses in T cells and 
macrophages from WT and BRP-39/ mice and evaluated 
the effects of recombinant (r) BRP-39 in these experimental 
systems. In the experiments with spleen-derived T cells, the 
cells from BRP-39/ mice and WT mice that were cultured 
with FasL or TNF- in vitro manifested enhanced levels of 
apoptosis, caspase 3 activation, and Fas expression compared 
with untreated WT controls (Fig. 7 A and not depicted). These 
in vitro cell death responses were significantly ameliorated by 
incubation with rBRP-39 (Fig. 7 A and not depicted). Inter-
estingly, this effect was most prominent on spleen cells in late-
stage apoptosis (Annexin V+ PIlow) versus splenocytes that were 
in early apoptosis (Annexin V+ PI; unpublished data). Perito-
neal macrophages and alveolar macrophages from BRP-39/ 
mice also manifest enhanced levels of annexin V staining, Fas 
expression, and caspase 3 activation (Fig. 7 B and not depicted). 
These cell death responses were also ameliorated in a dose-
dependent fashion by rBRP-39 (Fig. 7 B and not depicted). 
Interestingly, in both cases, these BRP-39–induced protective 
responses were associated with enhanced levels of phosphory-
lation of the antiapoptotic mediator PKB/AKT (Fig. 7, A and B) 
and the enhanced expression of the apoptosis inhibitor Faim 3 
(not depicted). These studies demonstrate that BRP-39 is a di-
rect inhibitor of eosinophil, T cell, and macrophage death re-
ceptor–mediated apoptosis/cell death in vitro. They also 
demonstrate that the antiapoptotic effects of BRP-39 are not 
restricted to pulmonary cells and are associated with augmented 
PKB/AKT phosphorylation and Faim 3 induction.
BRP-39 regulation of alternative macrophage activation
The studies noted in the previous sections demonstrate that 
the accumulation of alternatively activated macrophages was 
with WT and null BRP-39 loci (3.2 ± 0.089 ng/ml vs. 3.3 ± 
0.074 ng/ml for IL-13 Tg/BRP-39+/+ vs. IL-13 Tg/BRP-
39/ mice). These studies demonstrate that BRP-39 is in-
duced by and plays a critical role in the pathogenesis of the 
IL-13 effector responses that generate inflammation and air-
way remodeling.
BRP-39 regulation of inflammatory cell apoptosis/cell death
To further understand the mechanisms by which BRP-39 
contributes to Th2 effector responses, we next compared the 
cell death responses of inflammatory cells in OVA-plus-alum–
sensitized and –challenged WT and BRP-39/ mice and IL-13 
Tg mice with WT and null BRP-39 loci. The OVA studies 
revealed enhanced levels of TUNEL and annexin V staining 
of lung and BAL CD4 cells, macrophages, and eosinophils in 
BRP-39/ mice (Fig. 5, A and B; Fig. S4; and not depicted). 
This included cells with enhanced levels of expression of an-
nexin V only (apoptosis) and cells that stained with annexin V 
and propidium iodide (PI; advanced apoptosis vs. mixed apop-
tosis and necrosis; Fig. 5 C). Additional mouse examples can 
be seen in Fig. S5. This in vivo cell death response was associ-
ated with enhanced macrophage, T cell and eosinophil, and 
Fas (CD95) surface expression (Fig. 5 D). In accordance with 
the findings with OVA, the blunted inflammatory responses 
Figure 6. Roles of BRP-39 in AKT phosphorylation and Faim 3 
expression. BALB/c WT (+/+) and BRP-39/ mice were sensitized and 
challenged with OVA (OVA+) or PBS (OVA). (A and B) FACS and real-time 
RT-PCR were used to evaluate the expression of phosphorylated Akt  
(A) and the levels of mRNA encoding Faim 3 (B), respectively. The values in 
A and B are the mean ± SEM of evaluations in a minimum of five animals 
and are representative of at least two separate evaluations. MFI, median 
fluorescence intensity. *, P < 0.05.
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many of the effects of rBRP-39 on alternative activation 
were comparable to the effects of rIL-4 (Fig. 7 C and Fig. S6). 
These studies demonstrate that BRP-39 is a direct stimulator 
of alternative macrophage activation and that these effects are 
not restricted to alveolar cell populations.
Effects of Tg YKL-40
The CC10 promoter, reverse tetracycline transactivator, and 
tetracycline-controlled transcriptional suppressor were next 
used to overexpress YKL-40 in the mouse lung (Fig. S7 A). 
These CC10-rtTA-tTS-YKL-40 Tg mice had an appropriately 
targeted and inducible transgene (BAL YKL-40, 400–450 ng/ml 
after 48 h of doxycycline [dox] administration; Fig. S7 B) and 
decreased at sites of Th2- and IL-13–induced inflammation 
in BRP-39–deficient mice. To determine if BRP-39 directly 
contributes to alternative macrophage activation and to eval-
uate the lung specificity of these effects, peritoneal macro-
phages and alveolar macrophages were obtained from WT 
mice and incubated with rBRP-39 or vehicle control. In 
these experiments, rBRP-39 caused a significant increase in 
arginase 1 activity and induced the expression of the macro-
phage mannose receptor (MMR) and MHC class II (Fig. 7 C 
and Fig. S6). It also induced the production of MDC/CCL22 
and thymus- and activation-regulated chemokine (TARC)/
CCL17 without altering the production of the M1 marker 
nitric oxide (Fig. S6 and not depicted). In these experiments 
Figure 7. Roles of BRP-39 in splenocyte and macrophage apoptosis/cell death and macrophage activation in vitro. (A) Splenocytes from 
C57BL/6 WT mice were incubated in the presence or absence of 100 ng/ml TNF- or 100 ng/ml FasL in the presence or absence of 10 µg/ml rBRP-39. The 
levels of annexin V staining, intracellular activated caspase 3, Fas expression, and AKT phosphorylation were evaluated. (B) Peritoneal macrophages were 
elicited from WT (+/+) and BRP-39/ mice and incubated in the presence or absence of the noted doses of rBRP-39. Annexin V staining, Fas expression, 
and the levels of phosphorylated AKT were evaluated. *, P < 0.05. (C) Peritoneal and alveolar macrophages were obtained from WT mice, incubated with  
5 ng/ml rBRP-39 or IL-4 for 48 h, and arginase 1 activity and the expression of MMR were assessed. The values are the mean ± SEM of evaluations in a 
minimum of five animals and are representative of at least three separate evaluations. MFI, median fluorescence intensity. *, P < 0.05.
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Figure 8. Effects of Tg YKL-40 on OVA-induced Th2 responses in C57BL/6 BRP-39/ mice. 8-wk-old WT mice, BRP-39/ mice, and mice that 
do not make BRP-39 but produce YKL-40 in their lung epithelial cells (BRP-39//YKL-40+) were sensitized and challenged as described in Materials and 
methods. (A–D) Mice were sacrificed 24 h after the last challenge, and BAL total cell (A), eosinophil (B), IL4+CD4+ Th2 cells (C), and MMR expression  
(D) were evaluated. (E) AHR was also addressed by comparing the airway resistance of OVA-sensitized and -challenged WT mice (open circles), BRP-39/ 
mice (open squares), YKL40 Tg mice (solid circles), BRP-39//YKL-40+ mice (solid triangles), and WT mice sensitized with OVA and challenged with PBS 
(solid squares). *, P < 0.05 vs. WT/PBS; **, P < 0.01 vs. WT/PBS; ***, P < 0.01 vs. BRP-39//OVA. (F) Mucus metaplasia was evaluated with D-PAS staining. 
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AKT (Fig. 9, C–E). Higher levels of Faim 3 mRNA were also 
seen in lungs from OVA-sensitized and -challenged YKL-40 
Tg mice (Fig. 9 F). In combination, these studies demonstrate 
that epithelial-targeted YKL-40 rescues the deficient Th2 re-
sponse in BRP-39/ mice and regulates alternative macro-
phage activation, Th2 cell accumulation, inflammatory cell 
apoptosis, PKB/AKT activation, and Faim 3 expression in the 
mouse lung.
BRP-39 versus AMCase
The 18-glycosyl-hydolase family contains molecules like BRP-
39/YKL-40, which do not degrade chitin, and true chitinases 
like AMCase. The studies in this manuscript use null mutant, 
Tg, and in vitro approaches to define the important roles that 
BRP-39 and YKL-40 play in Th2- and IL-13–induced re-
sponses. Prior studies from our laboratory demonstrated that 
AMCase also plays important roles in these responses (4). To 
shed light on the biology or these moieties, we compared the 
regulation and effector profiles of AMCase and BRP-39. In 
the initial studies, we compared the expression of BRP-39 and 
AMCase in mice that received in vitro–generated antigen-spe-
cific polarized Th1 or Th2 cells, followed by antigen challenge 
and Tg mice that expressed IL-13 or IFN- in the mouse 
lung. As previously described, AMCase was induced by the 
Th2 but not the Th1 cells (not depicted) (4). In contrast, 
BRP-39 was induced by the Th1 and Th2 cells (Fig. 10 A). 
As noted in this and our prior manuscript (4), IL-13 was a po-
tent stimulator of both 18-glycosyl-hydolase moieties (un-
published data). However, Tg IFN- only stimulated BRP-39 
(Fig. 10 B and not depicted).
We next compared the regulation and localization of 
BRP-39 and AMCase in lungs from antigen-challenged mice. 
In keeping with the observation that IL-13 is a potent stimu-
lator of both moieties, AMCase and BRP-39 were both 
induced at sites of antigen-driven Th2 inflammation (unpub-
lished data). Interestingly, double-label IHC also demon-
strated that both were induced in macrophages and epithelial 
cells (Fig. 10 C). However, only a subpopulation of these 
cells expressed both moieties, and the expression of BRP-39 
was frequently more prominent than AMCase in the epithe-
lial and macrophage populations (Fig. 10 C).
To gain additional insight into the effector properties of 
these moieties, we next compared the expression of BRP-39 
and AMCase in OVA-sensitized and -challenged and IL-13 
Tg mice with WT and null BRP-39 loci. In keeping with our 
demonstration that AMCase induction is IL-13 dependent 
and that IL-13 production is decreased in OVA-sensitized and 
-challenged BRP-39/ mice, AMCase production was also 
decreased in BAL fluids from these animals (Fig. 10 D). Inter-
estingly, although IL-13–induced inflammation and remodel-
ing were significantly decreased in the absence of BRP-39, 
normal lungs on gross and light microscopic examination after 
4 wk of dox administration (not depicted).
To define the effector functions of our transgene, two 
approaches were used. In the first, we bred the CC10-rtTA-
tTS-YKL-40 mice with the BRP-39/ mice to generate 
CC10-rtTA-tTS-YKL-40/BRP-39/ mice that did not pro-
duce BRP-39 and only produced YKL-40 in the epithelium 
of the lung. This allowed us to define the effects of YKL-40 
in the absence of potentially confounding responses induced 
by endogenously produced BRP-39 and gave us a clear win-
dow into the ability of Tg YKL-40 to rescue the defective 
Th2 response in BRP-39/ animals. As noted in previous 
sections, OVA-plus-alum sensitization and OVA challenge 
caused an impressive eosinophil- and mononuclear cell–rich 
inflammatory response, increased Th2 cytokine elaboration, 
increased accumulation of CD4 Th2 cells and alternatively 
activated macrophages, and increased AHR on methacholine 
challenge and mucus metaplasia (Fig. 8, A–F; and not 
depicted). In accordance with these findings, BRP-39 played 
an important role in the pathogenesis of each of these re-
sponses because each was significantly decreased in the BRP-
39/ mice and restored to levels comparable to those in WT 
animals by epithelial-targeted YKL-40 (Fig. 8, A–F; and not 
depicted). As also noted, inflammatory cell apoptosis and 
CD95 expression were increased in OVA-plus-alum–sensi-
tized and OVA-challenged BRP-39/ mice (Fig. 8, G and H). 
These responses were also abrogated by CC10 promoter–
driven expression of YKL-40 (Fig. 8, G and H).
Experiments were also undertaken with CC10-rtTA-tTS-
YKL-40 mice on a WT genetic background. These experi-
ments compared responses in mice with physiological and 
supraphysiologic levels of BRP-39/YKL-40. At baseline, Tg+ 
mice and WT controls exposed to normal water or dox-
treated water for up to 4 wk had similar levels of BAL cell 
recovery and BAL cell differentials and lungs that could not be 
differentiated upon histological evaluation (unpublished data). 
Differences in the methacholine responses of these mice, 
WT mice, BRP-39/ mice, and CC10-rtTA-tTS-YKL-40/
BRP-39/ mice were also not noted. (Fig. S8). These YKL-40 
Tg mice also had levels of BAL cell recovery and eosinophil 
recovery that were comparable to those in WT mice after 
OVA sensitization and challenge (unpublished data). How-
ever, dox-treated Tg mice had mildly enhanced levels of al-
ternatively activated macrophages at baseline (Fig. 9 A), 
modestly enhanced accumulation of alternatively activated 
macrophages 24 h after OVA sensitization and challenge, and 
modestly enhanced accumulation of alternatively activated 
macrophages and Th2 cells 2 wk after OVA sensitization and 
challenge (Fig. 9, A and B). In addition, the alveolar macro-
phages and Th2 cells from these mice manifest lower levels of 
annexin V and Fas expression and higher levels of activated 
(G and H) FACS analysis was used to assess alveolar macrophage annexin V+ (G) and Fas (H) expression. The values in A–E, G, and H are the mean ± SEM 
of evaluations in a minimum of five animals and are representative of two separate experiments. F is representative of five similar evaluations. MFI,  
median fluorescence intensity. *, P < 0.05; **, P < 0.01. Bars, 50 µm.
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Figure 9. Effects of Tg YKL-40. In A and B, YKL-40 Tg mice (YKL40 Tg+) and Tg negative () littermate controls were placed on dox, OVA sensitization 
and challenge were undertaken, and evaluations were performed 24 h and 2 wk later. (A and B) The levels of MMR expression (A) and the accumulation of 
IL-4– and IL-13–producing cells (B) in the BAL were evaluated. (C–E) YKL-40 Tg mice (YKL40 Tg+) and Tg negative () littermate controls were placed on 
dox, OVA sensitization and challenge were undertaken, and evaluations were performed 2 wk later. The expression of CD4 cell and macrophage annexin V 
(C), Fas (D), and the levels of activated Akt (E) were evaluated. *, P < 0.05. (F) The levels of Faim 3 mRNA were evaluated 24 h after the last challenge by 
real-time RT-PCR. The values are the mean ± SEM of evaluations in a minimum of five animals and are representative of two separate experiments. MFI, 
median fluorescence intensity. *, P < 0.05.
AMCase induction was not significantly altered. (Fig. 10 E). 
These studies demonstrate that IL-13 stimulates BRP-39 and 
AMCase via different mechanisms. They also demonstrate 
that the induction of AMCase is not sufficient to overcome 
the defect in IL-13–induced tissue responses in mice that lack 
BRP-39. In accord with this finding, BRP-39 was also a po-
tent stimulator of the alternative activation of TARC/CCL17 
and MDC/CCL22 production by peritoneal and alveolar 
macrophages (Fig. S6, Fig. S11, and not depicted). BRP-39 
was also a potent activator of mDC (Fig. S6). In contrast, 
AMCase did not have similar effects on macrophages or DCs 
(Fig. S6). When viewed in combination, these studies dem-
onstrate that although BRP-39 and AMCase share superficial 
similarities, they differ in their regulation, sites of production, 
and effector repertoire.
DISCUSSION
BRP-39 was discovered in mouse breast cancer cells (9). 
Subsequently, a variety of homologues were described in-
cluding human YKL-40, human HcGP-39, GP38K (porcine 
38-kD heparin-binding glycoprotein), bovine 39-kD whey 
protein, and Drosophila melanogaster imaginal disc growth factors 
JEM VOL. 206, May 11, 2009 
ARTICLE
1161
normal physiology and disease pathogenesis are poorly under-
stood. In fact, our limited understanding of the functions of 
these strongly conserved (and therefore, presumably, biologi-
cally important) moieties in mammals and man is believed to 
be one of the most pressing issues in chitinase/CLP biology (27). 
To address this issue, we generated and characterized BRP-
39/ mice, YKL-40–overexpressing Tg mice, and mice that 
were deficient in BRP-39 and expressed YKL-40 selectively 
in lung epithelial cells. Studies of these mice have added to 
our understanding of the biology of CLP by demonstrating 
that BRP-39 plays a critical role in the pathogenesis of Th2 
inflammation and IL-13–induced inflammation and remod-
eling. They also provide insights into the multifaceted mech-
anisms that underlie these effects by demonstrating that 
(8, 10, 23, 24). In the breast, the expression of BRP-39 is in-
creased during the glandular remodeling that is seen after the 
cessation of lactation (9). In Drosophila, BRP-39–like mole-
cules act as growth factors (23), and in porcine systems, GP38K 
induces the differentiation of cultured vascular smooth mus-
cle cells (10). Human YKL-40/HcGP-39 is also produced by 
chondrocytes and synovial cells where it regulates cell prolif-
eration and has mitogenic effects on fibroblasts and synovio-
cytes (8, 24). This limited body of information suggests that 
BRP-39/YKL-40 plays a role in tissue remodeling. Because 
the levels of HcGP-39/YKL-40 are elevated in a variety of 
human diseases, it has also been thought to contribute to 
pathological remodeling responses (2, 10, 12, 24–26). Surpris-
ingly, however, the roles of these BRP-39–like moieties in 
Figure 10. Comparisons of BRP-39 and AMCase. (A) The levels of mRNA encoding BRP-39 in mice that received antigen-specific in vitro–polarized 
Th1 or Th2 cells and were challenged with antigen (c, control). (B) BRP-39 expression was evaluated by RT-PCR in IFN- Tg mice and controls ().  
(C) AMCase and BRP-39 expression were localized in the lungs of 2-mo-old IL-13 Tg mice by double-label IHC (white arrows, colocalized; yellow arrows, 
AMCase; red arrows, BRP-39). (D and E) The levels of BAL AMCase were assessed in OVA-plus-alum–sensitized and OVA-challenged mice (D) and IL-13 Tg 
mice with WT and null BRP-39 loci (E). The values in D and E are the mean ± SEM of evaluations in a minimum of five animals and are representative of 
two separate evaluations. *, P < 0.05. Bars, 25 µm.
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is well documented in T cells, macrophages, and eosinophils 
(28, 29) and is triggered when ligands like FasL and TNF- 
activate surface death receptors such as Fas (CD95). The 
present studies demonstrate that BRP-39 and YKL-40 in-
hibit inflammatory cell apoptosis in vivo and in vitro. They 
also demonstrate that these protective responses are associated 
with the activation of the well known apoptosis inhibitor 
PKB/AKT and the more recently described death receptor 
apoptosis inhibitor Faim 3 (also called TOSO [reference 30]). 
They also demonstrate that the augmented cell death that is 
seen in the BRP-39–null mice is associated with the exagger-
ated expression of CD95 and that rBRP-39 ameliorates FasL- 
and TNF-–induced spleen cell death. These observations 
demonstrate that BRP-39/YKL-40 is an important inhibitor 
of CD95 expression and death receptor–mediated inflamma-
tory cell apoptosis. They also demonstrate that this protection 
is associated with and potentially mediated by PKB/AKT 
and/or Faim 3. This speculation is compatible with the 
known ability of PKB/AKT and Faim 3 to inhibit Fas-FasL–
induced cell death responses and the importance of Fas-mediated 
inflammatory cell apoptosis in the control of Th2 tissue 
inflammation (31–34).
Excess tissue fibrosis is a well documented consequence 
of chronic Th2 inflammatory responses, and IL-13 is believed 
to be a major mediator of these remodeling reactions (22). 
The airway fibrosis in the lung-targeted IL-13 Tg mice that 
were used in these studies is a well appreciated example of 
this relationship. Previous studies from our laboratory dem-
onstrated that these IL-13–induced fibrotic responses are me-
diated, in part, by the ability of IL-13 to stimulate TGF-1 (22). 
Thus, studies were undertaken to determine if the dimin-
ished levels of fibrosis in IL-13 Tg mice that lack BRP-39 are 
associated with decrements in TGF-1 induction. These 
studies provide insight into the mechanisms that BRP-39 
may use in this setting by demonstrating that TGF-1 induc-
tion is mediated by a partially BRP-39–dependent mecha-
nism in IL-13 Tg animals. It is important to point out, 
however, that these studies do not define a role for BRP-39 
in the pathogenesis of TGF-1–induced responses. This pos-
sibility will need to be addressed in separate evaluations.
Our studies demonstrate that BRP-39 is produced by mac-
rophages and epithelial cells at sites of Th2 inflammation. 
However, the importance of BRP-39 in each of these tissue 
compartments has not been defined. To begin to address this 
issue, we bred BRP-39/ mice with YKL-40 Tg mice to ob-
tain mice that were deficient in BRP-39 and produced YKL-40 
only in respiratory epithelial cells. We then compared the anti-
gen-induced responses in WT mice, BRP-39–null mice, and 
CC10-rtTA-tTS-YKL-40/BRP-39/ animals. These studies 
demonstrated that the selective expression of YKL-40 in lung 
epithelial cells is able to fully rescue the defective Th2 response 
in BRP-39/ mice. These observations also demonstrated 
that YKL-40 can effectively crosse species lines and is able to 
trigger BRP-39 pathways in mouse modeling systems. Addi-
tional investigation will be required to define the roles of mac-
rophage BRP-39 in lung biology.
BRP-39 and YKL-40 are important regulators of allergen 
sensitization and Th2 cytokine effector responses that aug-
ment IgE production, DC accumulation and activation, and 
alternative macrophage activation while inhibiting inflamma-
tory cell apoptosis and CD95 expression and inducing PKB/
AKT activation.
We initiated our studies of BRP-39 by comparing the al-
lergen-induced adaptive Th2 responses in WT and BRP-
39/ animals. These studies demonstrated that BRP-39/ 
mice do not mount robust antigen-induced Th2 inflamma-
tory reactions. Interestingly, similar defects were seen in ex-
periments with chitin–free and chitin-containing antigens, 
suggesting that chitin binding does not play an essential role 
in these reactions. Evaluations of the defective Th2 responses 
in these mice demonstrated that BRP-39/YKL-40 contrib-
utes to Th2 reactions via a variety of mechanisms. First, they 
demonstrate that BRP-39/ mice do not sensitize appropri-
ately after antigen exposure when assessed with lymphocyte 
proliferation assays or assessments of antigen-specific IgE. In 
accordance with these findings, they demonstrate that BRP-39 
is an important stimulator of DC accumulation and activation 
in this setting. However, our studies also demonstrate that 
BRP-39–deficient mice also have a significant defect in Th2 
cytokine-induced effector responses. This was readily appre-
ciated in the IL-13 Tg mice where, despite producing similar 
levels of Tg protein, inflammation and fibrosis were dimin-
ished in BRP-39–deficient animals. These defective IL-13–
induced responses and the diminished antigen-induced 
responses in BRP-39/ mice were associated with increased 
levels of CD4 T cell, macrophage, and eosinophil apoptosis, 
increased CD95 expression, and diminished levels of CD4 T 
cell and alternatively activated macrophage accumulation. In 
vitro studies also demonstrated that rBRP-39 can directly in-
hibit death receptor–induced T cell and macrophage apopto-
sis and induce alternative macrophage activation. These 
observations demonstrate that BRP-39 is an important in-
hibitor of death receptor–induced inflammatory cell apopto-
sis and M2 macrophage differentiation. They also suggest that 
the accelerated cell death responses and diminished M2 dif-
ferentiation that are seen in BRP-39/ mice play important 
roles in the pathogenesis of the defective IL-13 and Th2 re-
sponses in these animals. Based on these findings, one can 
envision how elevated levels of tissue and or circulating 
BRP-39/YKL-40 can enhance antigen sensitization, increase 
DC number and activation, inhibit inflammatory cell death, 
and augment the accumulation of T cells and alternatively 
activated macrophages, thereby regulating the intensity and 
natural history of Th2-dominated diseases such as asthma. 
These findings also provide a potential mechanism, through 
which YKL-40 can contribute to the severity and activity of 
diseases in which T cells and macrophages are believed to 
play important pathogenic roles, such as rheumatoid arthritis, 
diabetes, inflammatory bowel disease, pulmonary fibrosis, 
and atherosclerosis.
Many apoptotic signals engage the cell death machinery via 
the membrane (extrinsic) pathway. This apoptotic mechanism 
JEM VOL. 206, May 11, 2009 
ARTICLE
1163
describing the novel roles of these molecules in allergen sensiti-
zation, IgE induction, Th2 cytokine production, DC activation, 
and alternative macrophage activation. Lastly, they demonstrate 
that BRP-39 and YKL-40 are potent inhibitors of death recep-
tor–induced inflammatory cell apoptosis and that these protec-
tive responses are associated with the induction and activation of 
PKB/AKT and the enhanced expression of Faim 3. These stud-
ies validate BRP-39/YKL-40 as a therapeutic target against 
which interventions can be directed to control asthma or other 
Th2- or macrophage-mediated pathologies.
Materials and Methods
Genetically modified mice. C57BL/6 and BALB/c WT mice were ob-
tained from The Jackson Laboratory. Standard targeting approaches and ho-
mologous recombination were used to generate BRP-39–null embryonic 
stem cells and knockout mice (Fig. S1). Mice with null mutations in BRP-39 
were generated on a mixed 129/C57BL/6 background and subsequently 
bred for >10 generations onto a C57BL/6 or BALB/c background. CC10–
rtTA–IL-13 Tg mice were generated in our laboratory (20), bred onto a 
C57BL/6 background, and used in these studies. These mice use the Clara 
cell 10-kD protein (CC10) promoter and the rtTA (reverse tetracycline 
transactivator) to target IL-13 to the lung in a dox-inducible manner. Tg 
mice in which human YKL-40 was tightly and inducibly overexpressed 
(CC10-rtTA-tTS-YKL-40) in a lung-specific manner were generated using 
constructs and approaches that have been previously described by our labo-
ratory (Fig. S7) (42). Mice that lacked BRP-39 and produced YKL-40 only 
in pulmonary epithelial cells (CC10-rtTA-tTS-YKL-40/BRP-39/) were 
generated by breeding the CC10-rtTA-tTS-YKL-40 and BRP-39/ mice. 
Animal protocols were approved by the Yale University Institutional Animal 
Care and Use Committee (IACUC), and all experiments were performed 
according to the guidelines of the Yale University IACUC.
Generation of OVA-induced Th2 responses. To evaluate allergen-induced 
Th2 responses, OVA sensitization and challenge was accomplished using a 
modification of the protocols described previously by our laboratory (43). In 
brief, 6–8-wk-old mice were immunized with 10 µg OVA and 1 mg alum 
gel (Imject Alum; Thermo Fisher Scientific) on days 1 and 8. Sham-immunized 
mice received the same amount of saline and 1 mg alum. On days 19–21, the 
mice received a single 30-min exposure to aerosolized 1% OVA. 1 d after the 
last challenge, physiological responses were evaluated. At intervals, the mice 
were sacrificed, BAL was undertaken, and tissue responses were evaluated.
IHC. Single- and double-label IHC were undertaken as previously described 
by our laboratory (44). These studies used a polyclonal anti–BRP-39 pre-
pared in New Zealand white rabbits with peptides 224–243 of the BRP-39 
molecule conjugated with KLH. The specificity of the resulting antiserum 
was assessed using Western blot and solid-phase binding assays against recom-
binant mouse AMCase, YM-1, YM-2, BRP-39, oviductin, and chitotriosi-
dase (AstraZeneca) and the purified YM-1/2 protein in the crystals in lungs 
from IL-13 Tg mice (Fig. S9). Antibodies against pro–surfactant protein C 
(Millipore), CC10 (Santa Cruz Biotechnology, Inc.), CD45 (BD), and F4/80 
(eBioscience) were used to identify alveolar type II cells, airway epithelial 
cells, and macrophages, respectively. The specificity of the staining was evalu-
ated in experiments in which the primary antiserum was not used and experi-
ments that compared tissue samples from WT and BRP-39/ animals.
Generation of OVA-induced Th1 responses. To evaluate OVA-induced 
Th1 response, we used the protocols described previously by Becart et al. (45).
HDM extract sensitization and challenge. HDM sensitization and chal-
lenge was accomplished using modifications of the protocols previously de-
scribed by Zuleger et al. (46).
The 18-glycosyl-hydrolase family contains molecules 
with true chitinase activity, like AMCase, and molecules like 
BRP-39/YKL-40 that bind to but do not cleave these poly-
saccharides (1, 27). To date, the majority of the investigations 
of these moieties have focused on AMCase. These studies 
have revealed a complex effector profile with AMCase con-
tributing to the pathogenesis of adaptive Th2 inflammation 
in chitin-free experimental systems (4) and inhibiting type 2 
innate immune responses in chitin-driven experimental sys-
tems (7). The present studies demonstrate that BRP-39 and 
YKL-40 also play key roles in the pathogenesis of adaptive 
Th2 inflammation. Thus, one could be tempted to speculate 
that AMCase and BRP-39 play similar roles in this and other 
settings. However, upon deeper analysis it is becoming clear 
that this assumption is not correct. It is already well docu-
mented that these molecules differ in their ability to cleave 
chitin. Our data also demonstrates that, in contrast to our 
present understandings regarding AMCase, BRP-399 has 
similar effects in chitin-free and chitin-containing antigen-
driven systems. This finding suggests that the contributions of 
AMCase in this setting may also be independent of its chitin-
ase enzyme activity. Our studies also demonstrate that BRP-39 
and AMCase are regulated differently, are produced by only 
partially overlapping populations of cells, and differ in their 
ability to induce alternative macrophage activation and DC 
activation. In accord with these findings, we noted that al-
though BRP-39 is need to generate Th2 inflammation and 
AMCase induction in antigen-driven systems, once IL-13 is 
elaborated it induces AMCase via a BRP-39–independent 
mechanism. In addition, in the latter setting (the IL-13 Tg 
mice), AMCase induction was not able to rescue the defect in 
IL-13–induced inflammation and fibrosis in BRP-39–deficient 
animals. The literature is filled with examples of multigene 
families that were initially defined based on sequence or struc-
tural homologies and a small number of shared effector proper-
ties. However, in most cases, as more knowledge is obtained, 
differences are appreciated that clarify the unique roles that 
each family member plays in biology. Our data suggests that 
we will eventually obtain a similar level of insight into the 
18-glycosyl-hydrolase family members and understand more 
completely the relationship between AMCase and BRP-39. 
Our demonstration that BRP-39 is a critical mediator in Th2 
inflammation that regulates allergen sensitization, inflamma-
tory cell apoptosis, and M2 macrophage differentiation is in 
keeping with the important roles that M2 macrophages (35, 36), 
DC activation (37, 38), and inflammatory cell apoptosis (34, 
39–41) play in asthma and Th2 inflammatory responses. Ad-
ditional investigation will be required to determine if these 
effector responses are generalizable to other members of the 
18-glycosyl-hydrolase family and have contributed to the re-
tention of this family in species as diverse as plants and man.
In summary, these studies demonstrate that BRP-39/ 
YKL-40 is induced during and plays a critical role in the patho-
genesis of aeroallergen-induced Th2 inflammation and IL-13 
effector responses. They also highlight the many ways that 
BRP-39 and YKL-40 contribute to these responses by 
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Nitric oxide was evaluated using the standard Griess reaction by adding 50 µl 
of test solution to 96-well flat-bottomed plates containing 50 µl of Griess re-
agent (1% sulfanilamide/0.1% N-(1-naphthyl)ethylenediamine dihydrochlo-
ride/2.5% H3PO4). The production of TARC/CCL17, MDC/CCL22, and 
IL-12p49 were assessed using commercial ELISA kits (R&D Systems) as de-
scribed by the manufacturer.
TUNEL staining. DNA fragmentation and cell death were evaluated using 
TUNEL assays as previously described by our laboratory (42).
Spleen cell apoptosis/cell death evaluations. Harvested spleen cells un-
derwent hemolysis and were resuspended in RPMI 1640 (10% FCS) me-
dium for 24 h. When indicated, 100 ng/ml of mouse rTNF- (PeproTech), 
100 ng/ml of mouse rFasL (PeproTech), and/or 10 µg/ml of mouse rBRP39 
(MedImmune, Inc.) were added to the assay. Apoptosis and necrosis were 
assessed using flow cytometry to assess Annexin V, PI, CD95 (Fas), activated 
caspase 3, and phospho-Akt as previously described by our laboratory (50).
Quantification of lung collagen. Animals were anesthetized, right heart 
perfusion was accomplished, and the heart and lungs were removed en bloc. 
The collagen content of the right lung was determined by quantifying total 
soluble collagen using the Sircol Collagen Assay kit (Biocolor) according to 
the manufacturer’s instructions.
Passive transfer and activation of polarized Th1 and Th2 cells. Polar-
ized Th1 and Th2 cells were generated in vitro from OTII T cell receptor Tg 
mice and passively transferred into WT recipients that were then challenged 
with OVA or vehicle as described previously (54).
Statistics. All data were initially checked for normal/parametric distribution 
(Kolmogorov-Smirnov test). If parametric distribution was found, analysis of 
variance was applied to screen for differences among at least three groups. To 
compare two individual groups, Student’s t test was applied. If nonparamet-
ric distribution was found, the Kruskal-Wallis test was applied to screen for 
differences among at least three groups, followed by the Mann-Whitney U 
test (Wilcoxon rank-sum test) to compare two individual groups. Statistical 
analyses were performed using Prism 4.0 (GraphPad Software, Inc.) and 
STATA (version 8.2 for Windows; StataCorp LP).
Online supplemental material. Fig. S1 illustrates the constructs that were 
used to generate the BRP-39–null mutant mice. Fig. S2 demonstrates the 
role of BRP-39 in OVA-induced tissue inflammation. Fig. S3 uses FACS to 
define the regulation of Th2 cell accumulation by BRP-39. Fig. S4 demon-
strates that BRP-39 regulates OVA-induced inflammatory cell apoptosis. Fig. S5 
uses FACS to define the role of BRP-39 in OVA-induced inflammatory 
cell apoptosis. Fig. S6 compares the effects of BRP-39 and AMCase on macro-
phage and DC activation. Fig. S7 illustrates the constructs that were used to 
generate the YKL-40 Tg mice and the inducibility of these animals. Fig. S8 
illustrates the methacholine responsiveness of the PBS-challenged WT, BRP-
39/, YKL-40 Tg, and BRP-39//YKL-40 Tg mice. Fig. S9 shows the 
specificity of the antisera against BRP-39 and AMCase that were used in this 
study. Fig. S10 illustrates the gating strategy used in the FACS evaluations. 
Fig. S11 illustrates the ability of BRP-39 to regulate OVA-induced chemo-
kine production. The supplemental materials and methods include details of 
the methods that were used for HDM sensitization and challenge, flow cytom-
etry, and the assessments of AHR.
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Histological analysis. The lungs were removed en bloc, inflated at 25-cm 
pressure with PBS containing 0.5% low melting point agarose gel, fixed in 
Streck solution (Streck), embedded in paraffin, sectioned, and stained. He-
matoxylin and eosin (H&E), and D-PAS or Mallory’s trichrome stains were 
performed in the Research Histology Laboratory of the Department of Pa-
thology at the Yale School of Medicine.
Immunoblot analysis. 50 µg BAL fluids and/or lung lysates were subjected to 
immunoblot analysis using the polyclonal rabbit antiserum against BRP-39 
noted in the IHC section. These samples were fractionated by PAGE, transferred 
to membranes, and evaluated as described previously by our laboratory (47).
Quantification of BRP-39/YKL-40, AMCase, Th2 cytokines, and 
TGF-1. The levels of BRP-39 in BAL or lung lysates were evaluated by 
ELISA using an anti–BRP-39 rabbit polyclonal IgG for capture and biotinyl-
ated anti–BRP-39 followed by horseradish peroxidase–labeled streptavidin 
(GE Healthcare) for detection. This assay detects as little as 50 pg/ml rBRP-39. 
YKL-40 was also quantitated by ELISA using the assay provided by MedIm-
mune, Inc. and a commercial assay (Quidel Corporation). The absence of cross 
reactivity with other chitinase family members (AMCase and chitotriosidase) 
was confirmed using 100-ng/ml concentrations of purified recombinant pro-
teins. The levels of AMCase were measured using an ELISA (MedImmune, 
Inc.). The levels of BAL fluid Th2 cytokines and total TGF-1 (after acid 
activation) were measured by ELISA using commercial kits (R&D Systems) as 
directed by the manufacturer.
Assessment of antigen-induced splenocyte proliferation. Mice were 
sensitized i.p. with OVA in alum on days 1 and 8. On day 19, the mice were 
killed and the spleens removed. Single cell suspensions were prepared, and 
splenocytes were cultured in RPMI containing 10% FCS, 5 mM l-glutamine, 
and 100 U/ml penicillin/streptomycin for 72 h, either with media alone or in 
the presence of 100 µg/ml OVA. To assess proliferation, BrdU was added to 
the media according to the manufacturer’s protocol (BD). After 72 h, superna-
tants were removed for cytokine analysis, and proliferation was assessed by 
staining for BrdU according to the manufacturer’s protocol (BD). Samples 
were read using LSR2 running FACS DIVA software (BD) and further ana-
lyzed using FlowJo software (Tree Star, Inc.).
Quantification of OVA-specific IgE. The levels of OVA-specific IgE 
were measured according to the manufacturer’s protocol (MD Biosciences).
Quantification of BAL Muc5ac. The levels of Muc-5ac, a major mouse 
airway mucin, in BAL fluids were evaluated using slot blotting and immuno-
detection with anti–Mucin-5AC (45M1; Neo-Markers) as previously de-
scribed by our laboratory (48).
mRNA analysis. mRNA levels were assessed using real-time RT-PCR as 
previously described by our laboratories (42, 49). The sequences for the 
primers that were used were obtained from Primer Bank online (http://pga 
.mgh.harvard.edu/primerbank).
Flow cytometry. Whole lung cell suspensions were obtained and evaluated 
using methods previously described by our laboratory (50) and the gating 
strategy illustrated in Fig. S10.
Assessment of AHR. AHR was determined 24 h after the last OVA chal-
lenge (day 22) using previously described methods (51).
Assessments of macrophage activation. Alveolar macrophages and thio-
glycollate (3%)-elicited peritoneal macrophages were incubated in RPMI 
1640 plus 10% FCS for 48 h with or without 10 µg/ml rBRP39, 5 ng/ml 
IL-4, 10 mg/ml rAMCase, or 1 µg/ml of endotoxin (LPS). Before performing 
the arginase 1 bioassay (Bioassays Inc.), they were lysed in 0.5% Triton X-100 
containing Protease Inhibitor Cocktail tablets (Roche) (52). Surface expres-
sion of CD206 and MHC II was evaluated as described by Stein et al. (53). 
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